Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering

Area of Science:

• Biotechnology
• Immunology
• Oncology

Background:

• Antibody-based therapeutics precisely target cancer markers via variable domains.
• Fc domain engineering and glycosylation are key for potent antibody therapeutics.
• Fc effector functions, like ADCC, are crucial for anti-cancer activity.

Purpose of the Study:

• To review technological platforms for antibody glyco-engineering.
• To discuss the clinical landscape of glyco-engineered antibodies in cancer therapy.
• To highlight the role of Fc domain glycosylation in modulating antibody efficacy.

Main Methods:

• Analysis of Fc domain mutagenesis studies.
• Investigation of N-linked glycan modifications on Fc domains.
• Review of genetic engineering advancements in antibody production.
• Examination of clinical data for approved glyco-engineered antibodies.

Main Results:

• Fc variants engineered for optimal Fcγ receptor engagement enhance effector functions.
• Lack of core fucose on IgG Fc glycans boosts antibody-dependent cellular cytotoxicity (ADCC).
• High terminal sialylation of Fc glycans is linked to reduced inflammation.

Conclusions:

• Glyco-engineering offers a powerful strategy to fine-tune antibody therapeutics.
• Approved glyco-engineered antibodies (mogamulizumab, obinutuzumab) demonstrate clinical success.
• Further advancements in antibody glyco-engineering promise more effective cancer treatments.